EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer

Song Hu, Hao Ming, Qian He, Ming Ding, Hao Ding, Chong Li

Frontiers in Oncology · 08.04.2024 · 14

DOI: 10.3389/fonc.2024.1314301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 08.04.2024. Verfasst von Song Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Third Affiliated Hospital of Soochow University, Changzhou, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The epidermal growth factor receptor (EGFR) ex20ins mutation, as a rare subtype of mutation, has gradually attracted attention. Its heterogeneity is high, its prognosis is extremely poor, and the efficacy of existing traditional treatment plans is limited. In this study, we aimed to evaluate efficacy of high dose furmonertinib as a first-line treatment for EGFR ex20ins-positive NSCLC.

Methods

This is a retrospective, multi-center, non-interventional study. From May 2021 to March 2023, 9 NSCLC patients with EGFR ex20ins were enrolled. Efficacy and safety of 160 mg furmonertinib were evaluated. Objective response rate (ORR), disease control rate (DCR), median progression-free survival (PFS) and treatment related adverse events (TRAEs) were assessed.

Results

Of the evaluated patients, six patients experienced partial remission (PR), two patients experienced stable disease (SD) and one patient experienced progress disease (PD). Data indicated 66.7% ORR and 88.9% DCR. The median progression free survival (PFS) was 7.2 months (95% CI: 6.616 - 7.784). Besides, a longgest PFS with 18 months was found in one patient with p.H773_V774insGTNPH mutation. No ≥ level 3 adverse events have been found.

Conclusions

The study proved the potential efficacy of 160mg furmonertinib in patients with advanced NSCLC with EGFR ex20ins. Meanwhile, 160mg furmonertinib had a good safety profile.

Schlagwörter

Stichwörter der Autor:innen

exon 20 insertionfirst-line treatmentfurmonertinibnon-small cell lung cancerthe epidermal growth factor receptor

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Third Affiliated Hospital of Soochow University, Changzhou, China.
  • Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Division of Respiratory Disease, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.

Zitieren

APA

Hu, S., Ming, H., He, Q., Ding, M., Ding, H., & Li, C. (2024). A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1314301

Vancouver

Hu S, Ming H, He Q, Ding M, Ding H, Li C. A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1314301

BibTeX
@article{Hu2024,
  author = {Hu, Song and Ming, Hao and He, Qian and Ding, Ming and Ding, Hao and Li, Chong},
  title = {A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1314301}
}
Kostenlos starten →